Haverford Trust Company’s Elevance Health ELV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$324K Sell
1,107
-3
-0.3% -$986 ﹤0.01% 353
2025
Q4
$389K Buy
1,110
+3
+0.3% +$1.01K ﹤0.01% 328
2025
Q3
$358K Sell
1,107
-2,008
-64% -$625K ﹤0.01% 326
2025
Q2
$1.21M Hold
3,115
0.01% 215
2025
Q1
$1.35M Sell
3,115
-153
-5% -$61.4K 0.01% 202
2024
Q4
$1.21M Sell
3,268
-22
-0.7% -$9.21K 0.01% 206
2024
Q3
$1.71M Buy
3,290
+13
+0.4% +$6.95K 0.02% 185
2024
Q2
$1.78M Sell
3,277
-95
-3% -$50.2K 0.02% 182
2024
Q1
$1.75M Sell
3,372
-22
-0.6% -$10.9K 0.02% 182
2023
Q4
$1.6M Buy
3,394
+35
+1% +$16.2K 0.02% 178
2023
Q3
$1.46M Hold
3,359
0.02% 175
2023
Q2
$1.49M Sell
3,359
-39
-1% -$18K 0.02% 175
2023
Q1
$1.56M Buy
3,398
+190
+6% +$90.4K 0.02% 162
2022
Q4
$1.65M Sell
3,208
-470
-13% -$239K 0.02% 154
2022
Q3
$1.67M Sell
3,678
-98
-3% -$46.9K 0.02% 149
2022
Q2
$1.82M Buy
3,776
+150
+4% +$74.2K 0.02% 152
2022
Q1
$1.78M Sell
3,626
-120
-3% -$54.9K 0.02% 155
2021
Q4
$1.74M Sell
3,746
-625
-14% -$263K 0.02% 160
2021
Q3
$1.63M Sell
4,371
-91
-2% -$34.6K 0.02% 161
2021
Q2
$1.7M Buy
4,462
+297
+7% +$114K 0.02% 162
2021
Q1
$1.5M Hold
4,165
0.02% 157
2020
Q4
$1.34M Buy
4,165
+395
+10% +$121K 0.02% 145
2020
Q3
$1.01M Hold
3,770
0.02% 160
2020
Q2
$991K Sell
3,770
-2
-0.1% -$534 0.02% 155
2020
Q1
$856K Sell
3,772
-60
-2% -$16.4K 0.02% 158
2019
Q4
$1.16M Buy
3,832
+2,069
+117% +$569K 0.02% 161
2019
Q3
$423K Buy
1,763
+33
+2% +$9.04K 0.01% 223
2019
Q2
$488K Buy
1,730
+101
+6% +$27.6K 0.01% 211
2019
Q1
$467K Sell
1,629
-175
-10% -$50.6K 0.01% 213
2018
Q4
$474K Sell
1,804
-285
-14% -$78.4K 0.01% 206
2018
Q3
$572K Hold
2,089
0.01% 197
2018
Q2
$497K Sell
2,089
-151
-7% -$35K 0.01% 207
2018
Q1
$492K Buy
2,240
+515
+30% +$121K 0.01% 202
2017
Q4
$388K Buy
1,725
+615
+55% +$131K 0.01% 215
2017
Q3
$211K Hold
1,110
﹤0.01% 260
2017
Q2
$209K Buy
+1,110
New +$199K ﹤0.01% 250

Other funds holding ELV

Haverford Trust Company's ELV Position: Q1 2026 in Review

Haverford Trust Company reduced its Elevance Health (ELV) stake by 0.27% in Q1 2026, selling an estimated $986 and leaving 1,107 shares worth $324K. The position accounts for ﹤0.01% of the portfolio, ranked #353.

Haverford Trust Company first reported a position in ELV in Q2 2017 and has held it in 36 quarters since. The position peaked at $1.82M in Q2 2022. 1,462 funds tracked by Wall St. Rank hold ELV as of Q1 2026.

  • Haverford Trust Company held 1,107 shares of Elevance Health worth $324K as of Q1 2026.
  • Haverford Trust Company sold 3 Elevance Health shares in Q1 2026, an estimated $986.
  • Elevance Health made up ﹤0.01% of Haverford Trust Company's portfolio in Q1 2026, its #353 holding.
  • Haverford Trust Company first reported a position in Elevance Health in Q2 2017 and has held it in 36 quarters since.
  • Haverford Trust Company's Elevance Health position peaked at $1.82M in Q2 2022.
  • 1,462 funds tracked by Wall St. Rank held Elevance Health as of Q1 2026.

Based on Haverford Trust Company's 13F filing for Q1 2026, filed 11 May 2026.